Methys DX
Develops methylation-based liquid biopsy tests for monitoring cancer patients
Highlights
- New on EvolcAdded 2026-11-11
About Methys DX
Methys DX develops M*Detect kits that use proprietary methylation signatures to analyze circulating tumor DNA from patients with advanced cancers. The tests use digital PCR and are designed to support prognosis, tumor monitoring and early detection of recurrence.
The company’s work builds on research from laboratories at Université Paris Cité, CNRS, ESPCI and PSL. It is based in Paris, France, and was founded in 2021.
Product: M*Detect kits and methylation-marker panels for analyzing circulating tumor DNA using digital PCR.
Jobs at Methys DX
More biotech & pharma companies
Mexbrain
Develops dialysis-based medical devices to remove excess metals from the blood of patients with metal-related conditionsNew on EvolcMicrobs
Develops rapid microbiological testing equipment and consumables for quality-control laboratoriesNew on EvolcMicrophyt
Microalgae-based ingredients for health, nutrition, well-being and beauty businessesMimabs
Preclinical antibody and ADC development services for biotech, pharmaceutical and academic research partnersMinakem
Develops and manufactures active pharmaceutical ingredients for pharmaceutical and healthcare companiesNew on EvolcMitem Pharma
Develops and commercializes essential and niche medicines for patients with serious conditionsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Contact Form 7High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.